louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04311138: Effect of Community-based Reablement
Official title: The Effect of Community-based Reablement in Remote Areas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Long Term Care
Keywords: reablement
community
Lead sponsor: National Taipei University of Nursing and Health Sciences
Sponsor class: OTHER
First posted: 2020-03-17
Enrollment: 28
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims o investigate the effect of a diversified community-based reablement on motor function, cognitive function, performance in activities of daily living (ADL), and physical performance of older people living in remote areas. Older adults who are mobile but unstable were recruited from 6 public elderly day care centers in remote areas of the New Taipei City. Experimental group received a 10-wk diversified community-based reablement service including group exercise, cognitive training, health education for 1.5 hours, and individualized reablement for 1.0 hour, while control group received 1.5-hr group intervention and 1.0-hr placebo intervention. The de Morton Mobility Index (DEMMI), Saint Louis Mental Status Examination (SLUMS), Barthel Index (BI), Canadian Occupational Performance Measure (COPM), and the Short Physical Performance Battery (SPPB) including balance, gait speed, chair stand tests were evaluated twice before and after interventions. The results of the current study are expected to provide evidence in supporting a novel and diversified community-based reablement in remote areas.


Eligibility criteria: Inclusion Criteria:

* living in community and participating in public elderly day care centers in remote areas of the New Taipei City
* speaking with Chinese or Taiwanese
* DEMMI score of 39-67

Exclusion Criteria:

* diagnosed with moderate or severe cognitive impairment (CDR score of 2 or above)
* unable to understand or follow one step instruction

Primary outcomes:
measure: Change in mobility function
timeFrame: baseline and 10 weeks
measure: Change in cognitive function
timeFrame: baseline and 10 weeks
measure: Change in performance in activities of daily living
timeFrame: baseline and 10 weeks
measure: Change in occupational performance
timeFrame: baseline and 10 weeks
measure: Change in physical performance
timeFrame: baseline and 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taipei University of Nursing and Health Sciences
Study officials:
affiliation: National Taipei University of Nursing and Health Sciences
name: ChenYi Song
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06892938: Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring
Official title: Finger Worn Detection Via Electrocardiographic Ring of Atrial Fibrillation and ECG Waveform Analysis (FINDER-AF)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Atrial Fibrillation (AF)
Arrhythmias Cardiac
Tachycardia
Palpitations
Bradycardia
Keywords: Atrial Fibrillation
Wearable Monitor
Electrocardiogram
Ring
Lead sponsor: Everbeat
Sponsor class: INDUSTRY
First posted: 2025-03-25
Enrollment: 232
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with or without cardiac arrhythmic history who are 18 years or older and do not have an implanted cardiac device.

Brief summary: Everbeat is a finger-worn ring that has a built-in electrocardiogram (ECG). In this study the investigators ensure that the ECG as read by the everbeat correctly classifies heart rhythms and detects atrial fibrillation. Investigators will also correlate the everbeat ECG waveform with a clinical-grade FDA approved electrocardiogram to ensure it may be reliably interpreted by clinicians or other algorithms.

Detailed description: In this study the participant will obtain a simultaneous electrocardiogram from both the everbeat ring system and a clinical-grade diagnostic ECG machine for correlation and analysis.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older

Exclusion Criteria:

* Presence of pacemaker or defibrillator
* Inability to wear a ring in size range available

Primary outcomes:
measure: Rhythm classification
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: XIMED
state: California
city: Baton Rouge
country: United States
facility: Our Lady of Lake Hospital
state: Louisiana
city: Pittsburgh
country: United States
facility: Allegheny General Hospital
state: Pennsylvania
Study officials:
affiliation: Our Lady of Lake Hospital
name: Kenneth Civello, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03416738: Modeling Treated Recovery From Aphasia
Official title: (C-STAR) Center for the Study of Aphasia Recovery Modeling Treated Recovery From Aphasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aphasia
Stroke
Stroke, Ischemic
Aphasia, Broca
Aphasia, Global
Aphasia, Mixed
Aphasia, Jargon
Aphasia, Expressive
Aphasia, Conduction
Aphasia, Fluent
Aphasia, Anomic
Lead sponsor: University of South Carolina
Sponsor class: OTHER
Collaborators: name: National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted: 2018-01-31
Enrollment: 127
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Stroke is the leading cause of adult disability in the United States, and aphasia is common following a stroke to the left hemisphere of the brain. Aphasia therapy can improve aphasia recover; however, very little is known about how different patients respond to different types of treatments.

The purpose of this study is to understand how the following factors influence an individual's response to aphasia treatment: 1) biographical factors (e.g., age, education, gender), 2) post-stroke cognitive/linguistic abilities and learning potential, and 3) the location and extent of post-stroke brain damage. We are also interested in understanding the kinds of treatment materials that should be emphasized in speech/language treatment.

Overall, the goal of the current research is to inform the clinical management of post-stroke aphasia by identifying factors that can predict how an individual will respond to different treatment methods.


Eligibility criteria: Inclusion Criteria:

* Experienced a left hemisphere ischemic or hemorrhagic stroke At least 12 months post-stroke
* Primarily English speaker for the past 20 years
* Ability to provide informed written or verbal consent MRI-compatible (e.g., no metal implants, not claustrophobic)

Exclusion Criteria:

* History of a right hemisphere stroke (Bilateral stroke)
* Clinically reported history of dementia, alcohol abuse, psychiatric disorder, traumatic brain injury, or extensive visual acuity or visual-spatial problems
* Severely limited speech production and/or auditory comprehension that interferes with adequate participation in the therapy provided

Primary outcomes:
measure: Philadelphia Naming Test
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Columbia
country: United States
facility: University of South Carolina
state: South Carolina
Study officials:
affiliation: University of South Carolina
name: Julius Fridriksson, PhD, CCC-SLP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07022938: Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
Official title: Efficacy and Safety of a Tablet Containing Palmitoyethanolamide, Alpha Lipoic Acid, Vitamin B12, Vitamin B6 , Vitamin B1, Nicotinamide, Magnesium, Zinc, Vitamin E, and Superoxide of Dismutase in Individuals Receiving Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cancer
Neuropathy
Chemotherapy Induced Pain Neuropathy
Chemotherapy-Induced Peripheral Neuropathy
Keywords: cancer
neuropathy
chemotherapy induced neuropathy
supplement
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 71
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomised controlled placebo controlled study
Primary purpose: TREATMENT

Brief summary: Administration of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin B12, vitamin B6 , vitamin B1, nicotinamide, magnesium, zinc, vitamin E, and superoxide of dismutase in individuals receiving chemotherapy

Detailed description: Investigation of effectiveness and safety of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin B12, vitamin B6 , vitamin B1, nicotinamide, magnesium, zinc, vitamin E, and superoxide of dismutase in individuals receiving chemotherapy

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed patients with cancer that have not received yet their treatment
* Patients that will be treated with platinum agents or taxanes

Exclusion Criteria:

* Not receiving dietary supplement
* Have already neuropathy
* Have already started chemotherapy
* Patients with uncontrolled diabetes

  -- Patients with chronic kidney disease
* Patiens with recent cardiovascular incident

Primary outcomes:
measure: Neuropathic Pain Symptom Inventory
timeFrame: 6 months
measure: PAIN Detect score
timeFrame: 6 months
Secondary outcomes:
measure: Visual Analogue scale
timeFrame: 6 months
measure: Nerve conduction velocity
timeFrame: 6months
measure: Vibration perception threshold
timeFrame: 6 months
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: University General Hospital of Thessaloniki AHEPA
Study officials:
References:
Clinical trial NCT00160238: Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy
Official title: A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Meniere's Disease
Keywords: Meniere's disease
Vestibular neurotomy
Lead sponsor: Solvay Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.


Eligibility criteria: Inclusion Criteria:

* Patients who have undergone vestibular neurotomy for the treatment of disabling Menière's disease and who have confirmed vestibular areflexia

Exclusion Criteria:

* Other peripheral vestibular disease than Menière's disease
* Central vestibular disease
* Neurological disease
* Contraindication to betahistine
* Pregnant or lactating women

Primary outcomes:
measure: Patients who have undergone vestibular neurotomy for the treatment of disabling Menière's disease and who have confirmed vestibular areflexia
Secondary outcomes:
measure: Other peripheral vestibular disease than Menière's disease;Central vestibular disease; Neurological disease; Contraindication to betahistine; Pregnant or lactating women
Other outcomes:
Locations:
city: Marseille
country: France
facility: Site 1
Study officials:
affiliation: Solvay Pharmaceuticals
name: Global Clinical Director Solvay
role: STUDY_DIRECTOR
References:
Clinical trial NCT05750238: Relationship Between Stress, Anxiety, Depression, Sexual Function and Marital Adjustment in Nurses
Official title: Relationship Between Stress, Anxiety, Depression, Sexual Function and Marital Adjustment in Nurses
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stress
Anxiety Disorders
Sexual Behavior
Lead sponsor: T.C. ORDU ÜNİVERSİTESİ
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 302
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: female employees working in the nursing profession were included.

Brief summary: One of the factors that increase harmony in marriage is sexual life and sexual satisfaction (Erdinç, 2018). Sexual intercourse is one of the pillars of a successful family; accordingly, functionality in this area greatly affects marital adjustment (Atrian, 2018). Studies show an important relationship between sexual adjustment and marital adjustment (Türkseven et al., 2020; Begdeş, 2021). Negative workplace factors such as occupational stress and long working hours affect the physical and mental states of nurses (Oyeleye et al., 2013; Chesak et al., 2019).

This study was planned to determine the relationship between stress, anxiety, depression, sexual function and marital adjustment in nurses.


Eligibility criteria: Inclusion Criteria:

* Volunteer to participate in the research,
* Over the age of 18,
* Married,
* Those whose spouse is alive and living with their spouse will be included.

Exclusion Criteria:

* Having a chronic disease (hypertension, diabetes),
* Nurses who are pregnant,
* Those who use drugs that may affect sexual function (beta-blockers, antihypertensives, antidepressants, antipsychotics, etc.) will be excluded from the study.

Primary outcomes:
measure: Marriage Adjustment Scale Marriage Adjustment Scale
timeFrame: 3 hours
measure: Arizona Sexual Experiences Scale
timeFrame: 1 hour
measure: Depression, Anxiety and Stress 21 Scale (DASS-21)
timeFrame: 3 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ordu University
Study officials:
References:
Clinical trial NCT05669638: A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
Official title: A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Immunotherapy
ADR
Keywords: PD1
immunotherapy
Lead sponsor: Xuanwu Hospital, Beijing
Sponsor class: OTHER
First posted: 2023-01-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients receiving anti-PD1 immunotherapy

Brief summary: The goal of this observational study is to learn about in the development process of adverse reactions of anti-PD1 immunotherapy. The main question it aims to observe:

* The autoantibody profile of patients
* The adverse reactions of patients
* The changes of immune cells and cytokine in patients

Detailed description: The goal of this observational study is to learn about the development process of adverse reactions of anti-PD1 immunotherapy. The main question it aims to observe:

* The autoantibody profile of patients
* The adverse reactions of patients
* The changes of immune cells and cytokine in patients (e.g., T cell, B cell, IL-6, etc.)

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years old.
2. Receiving anti-PD1 immunotherapy

Exclusion Criteria:

1. Vital signs are unstable
2. Functional impairment of immune system caused by other diseases or other reasons, such as Systemic lupus erythematosus (SLE), AIDS, etc.

Primary outcomes:
measure: Autoantibodies
timeFrame: Day 1
measure: Autoantibodies
timeFrame: Week 9
measure: Autoantibodies
timeFrame: Week 21
measure: Autoantibodies
timeFrame: Week 33
measure: Autoantibodies
timeFrame: Week 45
measure: the change of immune-related adverse events
timeFrame: baseline to Week 45
Secondary outcomes:
measure: the immune cell (Including T cell, B cell, etc.)
timeFrame: Day 1
measure: the immune cell (Including T cell, B cell, etc.)
timeFrame: Week 9
measure: the immune cell (Including T cell, B cell, etc.)
timeFrame: Week 21
measure: the immune cell (Including T cell, B cell, etc.)
timeFrame: Week 33
measure: the immune cell (Including T cell, B cell, etc.)
timeFrame: Week 45
measure: the cytokine
timeFrame: Day 1
measure: the cytokine
timeFrame: Week 9
measure: the cytokine
timeFrame: Week 21
measure: the cytokine
timeFrame: Week 33
measure: the cytokine
timeFrame: Week 45
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xuanwu Hospital
state: Beijing
Study officials:
affiliation: Xuanwu Hospital, Beijing
name: Hongyan Li, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03121638: Safety Study of NBP608 in Healthy Adult Volunteers
Official title: An Open Label, Active Controlled, Parallel Group Phase I Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of NBP608 in Healthy Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Varicella Zoster
Immunization; Infection
Keywords: Varicella Vaccine
Herpes Zoster Vaccine
Lead sponsor: SK Chemicals Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-04-20
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: * Indication: Protection against varicella and herpes zoster
* Study Objectives

  * Primary: Safety and tolerability assessment after single dose administration of NBP608
  * Secondary: immunogenicity assessment after single dose administration of NBP608

Detailed description: This is a single-center, open label, active controlled, dose-escalation, parallel group study to assess the safety, tolerability and immunogenicity of NBP608 in healthy adult volunteers. Total of 150 healthy subjects aged 20 and over are enrolled, and each subject is administered with single dose of vaccine which is sequentially assigned to active group 1, 2 and study group 1\~3 in 1:1:1:1:1 ratio(30 subjects are enrolled at each groups) .

Eligibility criteria: Inclusion Criteria:

* Healthy adults aged 20 and over
* Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements
* Female subjects of post-menopausal (amenorrhea for 24 months) whose pregnancy tests was found negative at screening visit
* Subjects of seropositive for Varicella-Zoster virus at screening visit

Exclusion Criteria:

* Patients with herpes zoster
* Subjects with a history of vaccination for herpes zoster
* Pregnant or lactating women
* Participants in another clinical study within 4 weeks before vaccination in this study, etc.

Primary outcomes:
measure: Incidence Rate of Adverse Event
timeFrame: 42days after Investigation Product Vaccination
Secondary outcomes:
measure: Varicella Zoster Virus Antibody Titer Measured by FAMA(Fluorescent Antibody to Membrane Antigen)
timeFrame: 42days after Investigation Product Vaccination
measure: Varicella Zoster Virus Antibody Titer Measured by gpELISA(Glycoprotein Enzyme-Linked Immunosorbent Assay)
timeFrame: 42days after Investigation Product Vaccination
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
Study officials:
affiliation: Korea University Guro Hospital
name: Hee-jin Cheong
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05465538: SV2A in Older Adults
Official title: Effect of Cannabis Use on Synaptic Density in Older Adults
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Cannabis Use
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2022-07-19
Enrollment: 24
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using \[11C\]UCB-J PET imaging.


Eligibility criteria: Inclusion Criteria:

* Able to provide informed consent
* Male or female, aged ≥50 years
* No history of significant medical or neurological disease
* BMI ≤ 50
* If woman of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study and up to one month after completion of PET scans

Exclusion Criteria:

* Women with a positive pregnancy test or women who are lactating
* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits;
* History of a bleeding disorder or are currently taking anticoagulants
* Subjects who have donated blood within 8 weeks of the present study

Primary outcomes:
measure: Hippocampal synaptic density
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Connecticut Mental Health Center
state: Connecticut
Study officials:
affiliation: Yale University
name: Rajiv Radhakrishnan, MBBS, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03809338: Ovarian Functions in Flight Attendants
Official title: Evaluation of Antral Follicle Count and Amh Values in Women Working at Night and Flight Attendants
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ovarian Functions in Flight Attendants
Lead sponsor: Acibadem Fulya Hastanesi
Sponsor class: NETWORK
First posted: 2019-01-18
Enrollment: 300
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 50 flight attendants and 50 control patients

Brief summary: The aim of this study was to evaluate the effects of night sleep disorder and sleeplessness, excessive hours spent on flight and UV radiation exposure over ovarian function in flight attendant women.

Detailed description: The aim of this study was to evaluate the effects of night sleep disorder and sleeplessness, excessive hours spent on flight and UV radiation exposure over ovarian function in flight attendant women.

On the third day of the menstrual period, evaluate the number of antral follicle count will be examined and the level of hormones showing the ovarian functions will be measured in the blood sample given by the participant.

Eligibility criteria: Inclusion Criteria:

* day working women , 25-35 years old
* night working women , 25-35 years old
* flight attendant women, 25-35 years old

Exclusion Criteria:

* those who cannot enter the groups above

Primary outcomes:
measure: level of amh
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Acibadem Fulya Hospital
Study officials:
References: